Half of all vaccines produced globally never reach a patient. They are wasted — lost to heat and cold, spoiled in transit, abandoned in remote clinics without reliable refrigeration. This "cold chain" problem is one of the most persistent barriers to global immunization. A new development this week may have moved us closer to solving it.
UK-based biotech company Stablepharma has developed a powder version of the tetanus-diphtheria vaccine that can be stored at room temperature for up to one year before being mixed with water and injected. In a world-first phase one clinical trial involving 60 volunteers, the vaccine produced encouraging results — a major step toward transforming how vaccines are stored and delivered worldwide.
The findings were published in the journal eClinicalMedicine, part of The Lancet group, with scientists calling the results "encouraging." Professor Saul Faust, director of the UK's National Institute for Health and Care Research (NIHR), described the implications clearly: "Keeping vaccines cold from the factory to the patient is one of the biggest challenges facing immunisation programmes. Our study suggests that this vaccine can remain safe and effective without refrigeration. If larger studies confirm these findings, this technology could help transform the way vaccines are stored and delivered around the world."
The stakes are enormous. The World Health Organization estimates that around 50 percent of vaccines are wasted globally each year, and cold chain failures account for a significant share of those losses. In rural communities across Africa, Asia, and Latin America, electricity is unreliable and refrigeration is rare. Vaccines arrive by motorbike, boat, or foot. Every degree of temperature deviation carries the risk of rendering a dose ineffective.
Traditional tetanus-diphtheria vaccines are liquid formulations that must be stored at temperatures between 2°C and 8°C. Stablepharma's innovation uses a drying process — similar to freeze-drying but more cost-effective — to convert the vaccine into a stable powder. At the point of administration, a healthcare worker mixes the powder with sterile water to reconstitute the injection. The process adds moments to the vaccination procedure and requires no additional training.
Phase one trials are primarily designed to test safety rather than efficacy. The fact that 60 volunteers tolerated the powder vaccine well is an important signal, but researchers emphasize that larger studies are needed before the product could be deployed at scale. If phase two and three trials confirm both safety and immunogenicity, Stablepharma's technology could be licensed to vaccine manufacturers worldwide — potentially making the product available in the highest-need regions within a decade.
Tetanus and diphtheria remain significant health threats in lower-income countries. Tetanus kills tens of thousands of people annually, with a disproportionate burden on newborns and their mothers. Diphtheria outbreaks resurge wherever vaccination coverage lapses. A room-temperature-stable vaccine against both diseases could dramatically improve protection in exactly the places that need it most.
The result also opens a broader door. If a powder format works for tetanus-diphtheria, it could be adapted to other vaccines. Stablepharma has indicated it is working on thermostable formulations for additional diseases, with polio and measles both on the research roadmap.
The timing of this breakthrough aligns with growing momentum around what researchers call "vaccine equity." The COVID-19 pandemic exposed how supply chain vulnerabilities — including cold chain logistics — can prevent life-saving vaccines from reaching people in lower-income countries. International funders including Gavi, the Vaccine Alliance, have made cold-chain independence a stated priority in their global health strategies.
For now, the encouraging phase one results represent a proof of concept that thermostability in injectable vaccines is achievable. The road ahead is long — clinical testing, regulatory approvals, manufacturing scale-up — but the direction is clear. A world where vaccines work without a fridge is within reach.
